The FDA determined the shortage of Eli Lilly And Co’s (NYSE:LLY) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) ...

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on ...

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

NHS England plans a phased rollout of tirzepatide to treat severe obesity, with early trials showing significant weight loss.

Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...

NHS England has asked NICE to consider a slow phased rollout of tirzepatide for weight loss in primary care to avoid overwhelming GPs.

Telehealth companies and patients are grappling with the potential loss of access to cheaper, alternative versions of Eli ...

Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

NHS leaders are considering a phased rollout of the obesity injection tirzepatide (Mounjaro, Eli Lilly) because of potentially high demand. The National Institute for Health and Care Excellence (NICE) ...